CD-ROM and Video iPOD of the FDA Regulatory and Compliance Symposium on the Campus of Harvard University Available
  • Managing Risks - From Pipeline to Patient
  • August 22 - 25, 2006
  • Classes Held in Harvard University's Annenberg Hall and Sanders Theatre, Cambridge, MA
Phone: 800-684-4549

CAMBRIDGE, MA USA -- HEALTHCARE UPDATE NEWS SERVICE(TM) -- SEPTEMBER 18, 2006: The Second FDA Regulatory and Compliance Symposium, August 22 - 25, 2006, on the campus of Harvard University announced today that two media platforms are available with the full content of the Symposium:

  • A CD-ROM which includes video and synchronized PowerPoint slides for all plenary sessions and audio and PowerPoint slides for all concurrent sessions, and
  • A video iPOD preloaded with conference plenary sessions and concurrent sessions audio.

The CD-ROM offers plenary session video with synchronized PowerPoint slides and concurrent sessions audio.

Easily navigate using your computer to the presenter and the exact content you wish to view.


Alternatively receive a new Video iPOD preloaded with Colloquium content.

Get Apple's Video iPOD yet, pre-loaded with the complete video of the Plenary sessions from the FDA Symposium (please note that the video on the iPODs does not include synchronized PowerPoint slides).


Order both the CD-ROM video content and the Video iPOD.

Thomas W. Abrams, RPh, MBA
Director, Division of Drug Marketing, Advertising, and Communications, CDER, FDA, Washington, DC
Peter B. Bach, MD, MAPP
Senior Advisor, Office of the Administrator, Centers for Medicare & Medicaid Services, Washington, DC
Sheldon Bradshaw, Esq.
Chief Counsel, FDA, Washington, DC
Igor Cerny, Pharm.D.
Director, Advisors and Consultants Staff, Office of Executive Programs, Center for Drug Evaluation and Research, FDA, Washington, DC
Jon E. Clark
Associate Director for Policy Development and GMP, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Washington, DC
Richard Cooper, JD
Partner, Williams & Connolly, LLP, Former Chief Counsel, Office of the General Counsel, FDA, Washington, DC
Scott Gottlieb, MD
Deputy Commissioner for Medical and Scientific Affairs, Office of the Commissioner, FDA, Washington, DC
David J. Horowitz, Esq.
Deputy Associate Commissioner for Compliance Policy, Office of Regulatory Affairs, FDA, Washington, DC
CAPT Paul J. Seligman, MD, MPH
Associate Director for Safety Policy and Communication, Center for Drug Evaluation and Research, FDA, Silver Spring, MD
James Sheehan, Esq.
Associate United States Attorney, U.S. Attorney's Office for the Eastern District of Pennsylvania, Philadelphia, PA
Daniel Troy, Esq.
Partner, Sidley Austin Brown & Wood, Former Chief Counsel, Office of the General Counsel, FDA, Washington, DC

Jane E. Henney, MD
Senior Vice President and Provost for Health Affairs, University of Cincinnati Academic Health Center; Former Commissioner, FDA, Cincinnati, OH
Philip J. Hilts
Former Science Reporter, The New York Times and The Washington Post; Lecturer, Department of Journalism, Boston University; Author, Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation and RX for Survival: Why We Must Rise to the Global Health Challenge; Winner, 2004 Los Angeles Times Book Prize for Science and Technology and The New York Times Notable Book of the Year distinction, Brookline, MA
John F. Kamp, J.D., Ph.D.
Executive Director, Coalition for Healthcare Communication; Of Counsel, Wiley Rein & Fielding LLP, Washington, DC
Wayne L. Pines
President, Regulatory Services and Healthcare, APCO Worldwide; Former Associate Commissioner for Public Affairs, FDA, Washington, DC
Peter J. Pitts
President, Center for Medicines in the Public Interest; Senior Vice President for Global Health Affairs, Manning, Selvage & Lee; Former Associate Commissioner for External Relations, FDA, New York, NY
Eric J. Topol, MD
Professor, Department of Genetics, Case Western Reserve University, Cleveland, OH


Rarely have there been so many major changes and uncertainties with such far-reaching consequences to drug development, manufacturing, monitoring and marketing. And rarely has there been a greater need to bring together representatives and advisors from government and the world's leading drugmakers to share strategies for regaining consumer confidence in today's medicines.

The FDA Regulatory and Compliance Symposium-a unique three-day, high-level forum in one of the world's most famous academic settings-will help drugmakers prepare for the full impact of all the changes flowing from the FDA and Congress, while clarifying many of the uncertainties. The Symposium will also provide practical, state-of-the-art solutions to the challenges of eliminating or reducing risks throughout the product life-cycle-from the drug pipeline to manufacturing to patient delivery.

The Symposium takes place on the campus of Harvard University. Classes are held in Annenberg Hall of the Sanders Theatre Complex. Inspired by the great halls of Oxford and Cambridge Universities, this room is arguably the most impressive space at Harvard. Harvard University, the oldest institution of higher learning in the United States, was established in 1636. Today, Harvard has grown to become a great undergraduate and graduate research university.

Arthur Miller, Esq.
Bruce Bromley Professor of Law
Harvard Law School
Cambridge, MA

"It is my pleasure to welcome attendees of the FDA Symposium to the campus of Harvard University. I hope that you will take advantage of this unique experience to study key Food and Drug Administration regulatory and compliance issues in this extraordinary academic environment."



Order the CD-ROM, Video iPOD or both online at: